文献速递帕金森病与运动障碍认知障碍与痴呆

皮质基底节综合征的临床影像学与神经病理学评估

Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome.
PubMed 文献 · Neurology · 2023-06-02

该研究回顾了113例临床诊断为皮质基底节综合征(CBS)患者的临床、脑MRI和神经病理资料,发现CBS可由多种神经退行性疾病引起,其中皮质基底节变性(CBD)仅占38%,临床和区域影像差异有助于预测潜在神经病理,现行CBD诊断标准在CBS患者中的阳性预测值(PPV)为40%。

要点

  • CBS患者尸检神经病理异质,CBD占38%,PSP占24%,AD占15%。
  • CBS-AD和CBS-DLBD/AD患者死亡年龄最小,CBS-PSP患者最大。
  • 临床和区域影像差异有助于预测CBS潜在神经病理。

核心结论

  • CBS患者可识别出多种神经退行性疾病,临床和区域影像差异有助于预测潜在神经病理。
  • 现行CBD诊断标准在CBS患者中阳性预测值(PPV)分析显示性能欠佳,需要对CBD足够敏感和特异的生物标志物。

研究设计与样本

  • 回顾性分析在Mayo Clinic随访并生前诊断为CBS的患者,按尸检神经病理类别回顾临床数据、脑MRI和神经病理数据。
  • 队列共113例CBS患者,其中女性61例(54%)。
  • 平均±标准差病程7±3.7年,平均±标准差死亡年龄70.5±9.1岁。

主要发现

  • 主要神经病理诊断:43例(38%)CBD,27例(24%)进行性核上性麻痹(PSP),17例(15%)阿尔茨海默病(AD),10例(9%)额颞叶变性(FTLD)伴TAR DNA结合蛋白43(TDP)包涵体,7例(6%)弥漫性路易体病(DLBD)/AD,9例(8%)其他诊断。
  • CBS-AD或CBS-DLBD/AD患者死亡年龄最小(中位数[四分位距]:64[13]、64[11]岁),CBS-PSP患者最大(77[12.5]岁,p=0.024)。
  • CBS-DLBD/AD患者病程最长(9[6]年),CBS-其他患者最短(3[4.25]年,p=0.04)。
  • 后皮质体征和肌阵挛更常见于CBS-AD和CBS-DLBD/AD患者,CBS-DLBD/AD患者显示更多路易体痴呆特征。
  • 基于体素的形态学分析显示CBS-AD广泛皮质灰质丢失,CBS-CBD和CBS-PSP主要累及前运动区伴更多白质丢失,CBS-DLBD/AD显示局灶顶枕区萎缩,CBS-FTLD-TDP显示前额叶皮质丢失,CBS-PSP中脑/脑桥比值最低(p=0.012)。

关键数值与推荐

  • 现行CBD诊断标准在CBS患者中的阳性预测值(PPV)为40%(67例符合可能CBD临床标准者中27例病理证实为CBD)。
  • CBS-PSP患者中脑/脑桥比值最低(p=0.012)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Corticobasal syndrome (CBS) is a clinical phenotype characterized by asymmetric parkinsonism, rigidity, myoclonus, and apraxia. Originally believed secondary to corticobasal degeneration (CBD), mounting clinicopathologic studies have revealed heterogenous neuropathologies. The objectives of this study were to determine the pathologic heterogeneity of CBS, the clinicoradiologic findings associated with different underlying pathologies causing CBS, and the positive predictive value (PPV) of current diagnostic criteria for CBD among patients with a CBS. METHODS: Clinical data, brain MRI, and neuropathologic data of patients followed at Mayo Clinic and diagnosed with CBS antemortem were reviewed according to neuropathology category at autopsy. RESULTS: The cohort consisted of 113 patients with CBS, 61 (54%) female patients. Mean ± SD disease duration was 7 ± 3.7 years; mean ± SD age at death was 70.5 ± 9.1 years. The primary neuropathologic diagnoses were 43 (38%) CBD, 27 (24%) progressive supranuclear palsy (PSP), 17 (15%) Alzheimer disease (AD), 10 (9%) frontotemporal lobar degeneration (FTLD) with TAR DNA-binding protein 43 (TDP) inclusions, 7 (6%) diffuse Lewy body disease (DLBD)/AD, and 9 (8%) with other diagnoses. Patients with CBS-AD or CBS-DLBD/AD were youngest at death (median [interquartile range]: 64 [13], 64 [11] years) while CBS-PSP were oldest (77 [12.5] years, p = 0.024). Patients with CBS-DLBD/AD had the longest disease duration (9 [6] years), while CBS-other had the shortest (3 [4.25] years, p = 0.04). Posterior cortical signs and myoclonus were more characteristic of patients with CBS-AD and patients with CBS-DLBD/AD. Patients with CBS-DLBD/AD displayed more features of Lewy body dementia. Voxel-based morphometry revealed widespread cortical gray matter loss characteristic of CBS-AD, while CBS-CBD and CBS-PSP predominantly involved premotor regions with greater amount of white matter loss. Patients with CBS-DLBD/AD showed atrophy in a focal parieto-occipital region, and patients with CBS-FTLD-TDP had predominant prefrontal cortical loss. Patients with CBS-PSP had the lowest midbrain/pons ratio (p = 0.012). Of 67 cases meeting clinical criteria for possible CBD at presentation, 27 were pathology-proven CBD, yielding a PPV of 40%. DISCUSSION: A variety of neurodegenerative disorders can be identified in patients with CBS, but clinical and regional imaging differences aid in predicting underlying neuropathology. PPV analysis of the current CBD diagnostic criteria revealed suboptimal performance. Biomarkers adequately sensitive and specific for CBD are needed.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shir D, Pham NTT, Botha H, et al. Clinicoradiologic and Neuropathologic Evaluation of Corticobasal Syndrome. Neurology. 2023. PMID: 37268436. doi:10.1212/WNL.0000000000207397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。